ASTRO Commends Passing of Bill to Reduce Prior Authorization Burden and Treatment Delays
The US House of Representatives passed the Improving Seniors' Timely Access to Care Act of 2021 (H.R. 3173), which was introduced in the House in May 2021 by Representatives Suzan DelBene (D-Wash.), Mike Kelly (R-Pa.), Ami Bera, MD (D-Calif.) and Larry Bucshon, MD (R-Ind.) and ultimately amassed 323 of the 435 members of the House as co-sponsors. A complementary bill was introduced in the Senate (S. 3018) in October 2021 by Senators Roger Marshall, MD (R-Kan.), Kyrsten Sinema (D-Ariz.), John Thune (R-S.D.) and Sherrod Brown (D-Ohio); that bill currently has 42 bipartisan Senate co-sponsors.
The American Society for Radiation Oncology (ASTRO) applauded the House passage of bipartisan federal legislation that would rein in restrictive prior authorization practices that delay patient access to critical cancer treatments with the following statement from Laura A. Dawson, MD, FASTRO, Chair of the ASTRO Board of Directors:
“This legislation is an essential step in the effort to reform the broken prior authorization system, and we applaud the overwhelming and bipartisan support shown by House members in addressing this persistent pain point for our nation’s patients and physicians.
Obstructive prior authorization practices create unnecessary delays for clinically appropriate, evidence-based treatments. These disruptions cause added anxiety for people who need life-saving cancer treatments, as delays in the start of radiation therapy are associated with worse outcomes for people with cancer. Prior authorization also wastes critical time and resources for clinics that are still rebounding from the ongoing pandemic.
With today's House vote, policymakers are helping to bring much-needed transparency and oversight to the prior authorization process for Medicare Advantage, which will lead to fewer treatment delays for beneficiaries and less administrative burden for clinics nationwide. Given the similarly broad bipartisan support of the bill in the Senate, we urge Senate leadership to vote on the bill and pass it expeditiously so it can be signed into law.”
Prior authorization is consistently ranked by radiation oncologists as the biggest challenge facing their clinics. Nine in 10 radiation oncology practice leaders say their patients are delayed from cancer treatment due to prior authorization, and a majority say the average delay lasts a week or longer. Research has linked each week of delay in starting cancer therapy with a 1.2% to 3.2% increased risk of cancer death.
While radiation oncology faces the most prior authorization hurdles of any medical specialty, these problems stretch across the American health care system. An April 2022 report from the inspector general’s office of the Health and Human Services Department concluded that 13% of Medicare Advantage prior authorization requests, or about 85,000 beneficiaries, were improperly denied in 2019.
The Council for Affordable Quality Healthcare estimated that $686 million in spending was associated with conducting prior authorizations in 2021. A separate study calculated a $40 million annual financial impact for the time required to secure approvals at academic radiation oncology clinics.
Call for Papers
ARO is seeking original case reports, research articles, and review articles on innovative topics offering practical applications in radiation oncology. Manuscripts undergo a double-blinded external peer review process, and there is no submission fee.
- First Clinical Results Published for 177Lu-rhPSMA-10.1 in mCRPC Trial
- Opaganib Shown to Protect Against Radiation-Induced Lung Inflammation
- Fusion Licenses Actinium-Based PSMA Targeted Radiotherapy From Heidelberg University and Euratom
- Future of Theranostics in Neurooncology Looks Promising With Recent Advancements
- First Cellular Therapy for Unresectable or Metastatic Melanoma Receives FDA Approval